背景:阵发性室上性心动过速(PSVT)是急诊科常见的心律失常。改良Valsalva手法(MVM)和静脉腺苷都是一线治疗,其中前者成功率较低,而后者成功率较高,但存在一些风险和不利影响。考虑到这两种快速的反向节奏,将它们结合起来可以达到更好的效果。
目的:本研究的目的是评估在MVM治疗阵发性室上性心动过速(pSVT)时联合使用静脉注射腺苷的成功率和潜在风险。
方法:我们招募了2017年至2022年的pSVT患者,并将其随机分为3组,MVM组,静脉注射腺苷组,联合治疗组,其中MVM被允许执行两次,而静脉注射腺苷以滴定的方式重复三次,记录各组的成功率和副作用。
结果:MVM组的成功率,腺苷组,组合组为42.11%,75.00和86.11%,分别。腺苷组和联合组的成功率明显高于nMVSM组(p<0.01,p<0.001),而联合组的成功率高于腺苷组,无显著性差异(p=0.340)。在安全方面,最长的RR持续时间(心搏停止期)为1.61s,1.60秒,和2.27s,三组之间存在统计学差异(p<0.01),腺苷和联合组之间存在统计学差异(0.018)。
结论:因此,我们可以得出结论,联合治疗具有相对较高的成功率和良好的安全性,但是目前的研究未能显示出其对腺苷的优越性。
Paroxysmal supraventricular tachycardia (PSVT) is an arrhythmia commonly seen in the emergency department. Both modified Valsalva maneuver (MVM) and intravenous adenosine are the first line treatment, of which the former has e lower success rate while the latter has a higher success rate but some risks and adverse effects. Given both of these reverse rhythms quickly, combining them may achieve a better effect.
The objective of this study is to evaluate the success rate and potential risk of combining the use of intravenous adenosine while patients were doing MVM as a treatment for paroxysmal supraventricular tachycardia(pSVT).
We recruited patients with pSVT from 2017 to 2022, and randomly assigned them into 3 groups, MVM group, intravenous adenosine group, and combination therapy group, in which MVM was allowed to be performed twice, while intravenous adenosine was given in a titration manner to repeat three times, recorded the success rate and side effects in each group.
The success rate of the MVM group, adenosine group, and combination group are 42.11%, 75.00 and 86.11%, respectively. The success rate of the adenosine group and combination group is significantly higher than the n MVSM group (p < 0.01, p < 0.001), while the success rate of the combination group is higher than the adenosine group, it has no significant difference (p = 0.340). In terms of safety, the longest RR durations (asystole period) are 1.61 s, 1.60s, and 2.27 s, there is a statistical difference among the three groups (p < 0.01) and between the adenosine and combination group (0.018).
Therefore, we can conclude that combination therapy has a relatively high success rate and good safety profile, but the current study failed to show its superiority to adenosine.